Selective peroxynitrite-mediated protein nitration catalyzed by glyoxalase domain containing protein 4

S Sarah Wright V Vu C. Dang (Nitrase Therapeutics) S Sami Hussain (Nitrase Therapeutics) P Prasanna Kandel (Nitrase Therapeutics) R Robert P. Brendza (Nitrase Therapeutics) S Sahar Mazhar (Nitrase Therapeutics) M Marie Whitmore (Nitrase Therapeutics) S Selim Boudoukha (Nitrase Therapeutics) J Jaskamaljot Kaur Banwait (Department of Chemistry, The University of Alabama at Birmingham) R Robert Van Der Linden (Nitrase Therapeutics) E Edward Vertudes (Nitrase Therapeutics) K Kate Markham (Nitrase Therapeutics) M Marta Trzeciak G Grace Pohan (Nitrase Therapeutics) A Andy Jennings (Nitrase Therapeutics) S Sheerin Shahidi-Latham (Nitrase Therapeutics) F Frank Kayser (Nitrase Therapeutics) M Mike Beckstead (Oklahoma Medical Research Foundation) A Aaron L. Lucius (Department of Chemistry, The University of Alabama at Birmingham) A Arun Kashyap (Nitrase Therapeutics) H Harry Ischiropoulos (Children’s Hospital of Philadelphia Research Institute and University of Pennsylvania) I Irene Griswold-Prenner (Nitrase Therapeutics)

Abstract

Tyrosine nitration alters the structure, function, and cellular localization of proteins and is implicated in the pathology of multiple diseases [G. Ferrer-Sueta et al. , Chem. Rev. 118 , 1338–1408 (2018), H. Ischiropoulos, Arch. Biochem. Biophys. 356 , 1–11 (1998), I. Griswold-Prenner et al. , J. Biol. Chem. 299 , 105038–10554 (2023)]. Although protein nitration is assumed to proceed via nonspecific chemical mechanisms, it is highly selective, suggesting the possibility of enzymatic catalysis. Here, we showed that glyoxalase domain-containing protein 4 (GLOD4), a previously uncharacterized protein, is an enzyme that catalyzes selective protein nitration. A primary in vivo target for GLOD4-mediated nitration is alpha-synuclein (α-syn), which is central to the pathogenesis of Parkinson’s disease (PD) and related disorders. We document tyrosine nitration of α-syn by GLOD4 in vitro, in cells, and in a murine model of synuclein pathology. The data identified a function of GLOD4 and other structurally related proteins that catalyze the peroxynitrite-mediated selective protein tyrosine nitration. This enzymatic catalysis of nitration may unearth pathophysiological mechanisms and potential interventions in diseases such as PD, cancer, and autoimmunity.

Article Details

Volume / Issue Vol. 123, Issue 6
Published February 10, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (22)

S

Sarah Wright

V

Vu C. Dang

Nitrase Therapeutics

S

Sami Hussain

Nitrase Therapeutics

P

Prasanna Kandel

Nitrase Therapeutics

R

Robert P. Brendza

Nitrase Therapeutics

S

Sahar Mazhar

Nitrase Therapeutics

M

Marie Whitmore

Nitrase Therapeutics

S

Selim Boudoukha

Nitrase Therapeutics

J

Jaskamaljot Kaur Banwait

Department of Chemistry, The University of Alabama at Birmingham

R

Robert Van Der Linden

Nitrase Therapeutics

E

Edward Vertudes

Nitrase Therapeutics

K

Kate Markham

Nitrase Therapeutics

M

Marta Trzeciak

G

Grace Pohan

Nitrase Therapeutics

A

Andy Jennings

Nitrase Therapeutics

S

Sheerin Shahidi-Latham

Nitrase Therapeutics

F

Frank Kayser

Nitrase Therapeutics

M

Mike Beckstead

Oklahoma Medical Research Foundation

A

Aaron L. Lucius

Department of Chemistry, The University of Alabama at Birmingham

A

Arun Kashyap

Nitrase Therapeutics

H

Harry Ischiropoulos

Children’s Hospital of Philadelphia Research Institute and University of Pennsylvania

I

Irene Griswold-Prenner

Nitrase Therapeutics